How are you feeling on Semaglutide?

Common does not mean easy

Nausea, vomiting, diarrhea and constipation are common digestive effects in the Wegovy (semaglutide) label. A pooled analysis of the weight trials found most digestive events were mild or moderate and often appeared while study doses were being increased. That's a finding about groups of participants.

It doesn't tell you how serious your own symptom is. Feeling unwell is worth describing plainly, without trying to match the average or prove you can put up with it.

Say what changed

What happened, when did it start, and is it continuing? Can you eat and drink, and how much is it affecting daily life? Those details help a clinician assess the problem.

The label warns that severe digestive symptoms can cause fluid loss and kidney injury. It also warns about pancreatitis, inflammation of the pancreas, and gallbladder problems. Severe or persistent stomach pain, sometimes spreading to the back, is a pancreatitis warning sign described in the label.

Severe symptoms or a possible emergency need urgent medical care. A routine message queue cannot provide emergency assessment.

Some risks start with the health history

The boxed warning concerns tumors in thyroid C cells, a particular type of thyroid cell, seen in rodents. Whether this rodent finding applies to people taking semaglutide is still unknown. The label rules out use with a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer. It also rules out use with multiple endocrine neoplasia type 2, an inherited condition called MEN 2.

A previous serious allergic reaction to semaglutide or a product ingredient also rules out use. The label says Wegovy is not recommended with severe gastroparesis, which means the stomach empties very slowly.

For people with type 2 diabetes, insulin and some other diabetes medicines can raise the risk of low blood sugar when combined with semaglutide. In SUSTAIN-6, a trial in people with type 2 diabetes at high risk of heart or blood-vessel disease, diabetic eye-disease complications occurred more often with semaglutide than placebo. The increase was larger in people who already had diabetic eye damage. That finding deserves its own discussion, rather than reassurance that any worsening is temporary.

Pregnancy plans and procedures matter

The Wegovy label instructs prescribers to discontinue it at least two months before a planned pregnancy because it stays in the body so long. That's the label's instruction to prescribers, not a treatment plan from this page. Pregnancy plans need a conversation with the clinician responsible for care.

The label also describes rare reports of stomach contents entering the lungs during anesthesia or deep sedation. It asks prescribers to tell patients to inform the procedure team that they take Wegovy. It does not establish one stopping rule for everyone.

Make the next contact clear

Who reviews a symptom between appointments, and which concerns need faster attention? We'd want that settled before relying on a routine message. A clear route back to care matters as much as the first conversation.

Our follow-up page looks beyond the weigh-in. Whether treatment is tolerable, what else has changed and whether the plan still fits all belong in that review.